Related Experiment Video
Updated: Jul 15, 2026
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Toward better renoprotection: lessons from angiotensin receptor blockers
Toshio Miyata1, Shunya Takizawa
1Division of Nephrology, Hypertension and Metabolism, Tokai University School of Medicine, Kanagawa, Japan. t-miyata@is.icc.u-tokai.ac.jp
Hemodialysis International. International Symposium on Home Hemodialysis
|April 4, 2007
Summary
Chronic kidney disease (CKD) is a global health crisis with limited treatments. Angiotensin II receptor blockers offer kidney protection beyond lowering blood pressure, opening new therapeutic avenues.
Area of Science:
- Nephrology
- Pharmacology
- Molecular Medicine
Background:
- Chronic kidney disease (CKD), particularly diabetic nephropathy, represents a significant global health burden.
- Current therapeutic strategies for preventing or slowing CKD progression are limited.
- Understanding the molecular underpinnings of CKD is crucial for developing effective interventions.
Purpose of the Study:
- To explore the renoprotective effects of antihypertensive agents targeting the renin-angiotensin system.
- To investigate the mechanisms of kidney protection offered by angiotensin II type 1 receptor blockers (ARBs) beyond their blood pressure-lowering effects.
Main Methods:
- Review of scientific literature on CKD, diabetic nephropathy, and renin-angiotensin system inhibitors.
- Analysis of studies investigating the molecular actions of ARBs in kidney disease models.
- Focus on evidence demonstrating renoprotective outcomes independent of systemic blood pressure reduction.
Main Results:
- Angiotensin II type 1 receptor blockers (ARBs) demonstrate significant renoprotective properties.
- These protective effects extend beyond the modulation of blood pressure.
- Specific molecular pathways targeted by ARBs contribute to kidney preservation.
Conclusions:
- ARBs represent a promising therapeutic class for managing CKD, particularly in diabetic nephropathy.
- Their renoprotection is mediated by mechanisms independent of systemic blood pressure reduction.
- Further research into these specific molecular actions could lead to novel CKD treatment strategies.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...